+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Erectile Dysfunction Drugs Market Research Report by Drug, Mode of Administration, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 252 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 4989691
UP TO OFF until Dec 31st 2022
The Global Erectile Dysfunction Drugs Market size was estimated at USD 2,103.97 million in 2021, USD 2,254.13 million in 2022, and is projected to grow at a CAGR of 7.31% to reach USD 3,213.51 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Erectile Dysfunction Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug, the market was studied across Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra, Staxyn).
  • Based on Mode of Administration, the market was studied across Injections, Oral, and Topical.
  • Based on End-User, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Erectile Dysfunction Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Erectile Dysfunction Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Erectile Dysfunction Drugs Market, including Apricus Biosciences Inc., Aurobindo Pharma Ltd, Bayer AG, Cipla Ltd, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Dr. Reddys Laboratories Ltd, Eli Lilly and Company, Endo International PLC, Ferring Pharmaceuticals, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc, Meda Pharmaceuticals, Inc., Metuchen Pharmaceuticals LLC, Mylan N.V., Novartis International AG, Pfizer, Inc., Promedon HQ, S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, and Vivus, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Erectile Dysfunction Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Erectile Dysfunction Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Erectile Dysfunction Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Erectile Dysfunction Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Erectile Dysfunction Drugs Market?
6. What is the market share of the leading vendors in the Global Erectile Dysfunction Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Erectile Dysfunction Drugs Market?
Frequently Asked Questions about the Global Erectile Dysfunction Drugs Market

What is the estimated value of the Global Erectile Dysfunction Drugs Market?

The Global Erectile Dysfunction Drugs Market was estimated to be valued at $2103.97 Million in 2021.

What is the growth rate of the Global Erectile Dysfunction Drugs Market?

The growth rate of the Global Erectile Dysfunction Drugs Market is 7.3%, with an estimated value of $3213.51 Million by 2027.

What is the forecasted size of the Global Erectile Dysfunction Drugs Market?

The Global Erectile Dysfunction Drugs Market is estimated to be worth $3213.51 Million by 2027.

Who are the key companies in the Global Erectile Dysfunction Drugs Market?

Key companies in the Global Erectile Dysfunction Drugs Market include Apricus Biosciences Inc., Aurobindo Pharma Ltd, Bayer AG, Cipla Ltd, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong, A Pharmaceutical Co. Ltd., Dr. Reddys Laboratories Ltd and Endo International PLC.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in patient awareness and education levels
5.1.1.2. Growing portion of geriatric population
5.1.1.3. Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
5.1.2. Restraints
5.1.2.1. Side effects associated with the erectile dysfunction drugs
5.1.3. Opportunities
5.1.3.1. Government reforms and public awareness initiatives in developing nations
5.1.3.2. R&D focused on developments of effective therapies and treatments for erectile dysfunction
5.1.4. Challenges
5.1.4.1. Availability of cost-effective counterfeit drugs
5.2. Cumulative Impact of COVID-19
6. Erectile Dysfunction Drugs Market, by Drug
6.1. Introduction
6.2. Avanafil (Stendra)
6.3. Muse Suppository (Alprostadil)
6.4. Sildenafil (Viagra)
6.5. Tadalafil (Cialis)
6.6. Vardenafil (Levitra, Staxyn)
7. Erectile Dysfunction Drugs Market, by Mode of Administration
7.1. Introduction
7.2. Injections
7.3. Oral
7.4. Topical
8. Erectile Dysfunction Drugs Market, by End-User
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Erectile Dysfunction Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Erectile Dysfunction Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Erectile Dysfunction Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Apricus Biosciences Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Aurobindo Pharma Ltd
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bayer AG
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Cipla Ltd
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Cristalia Produtos Quimicos Farmaceuticos Ltd.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Dong-A Pharmaceutical Co. Ltd.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Dr. Reddys Laboratories Ltd
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Eli Lilly and Company
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Endo International PLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Ferring Pharmaceuticals
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Futura Medical PLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. GlaxoSmithKline PLC
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Johnson & Johnson Services, Inc
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Meda Pharmaceuticals, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Metuchen Pharmaceuticals LLC
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Mylan N.V.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Novartis International AG
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Pfizer, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Promedon HQ
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. S.K. Chemicals Co. Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Teva Pharmaceutical Industries Ltd
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Torrent Pharmaceuticals Ltd
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Vivus, Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET DYNAMICS
FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2021 VS 2027 (%)
FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG, 2027
FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), 2018-2027 (USD MILLION)
FIGURE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), 2018-2027 (USD MILLION)
FIGURE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2021 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY MODE OF ADMINISTRATION, 2027
FIGURE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, 2018-2027 (USD MILLION)
FIGURE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
FIGURE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, 2018-2027 (USD MILLION)
FIGURE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 26. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USER, 2027
FIGURE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 30. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 31. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 33. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 34. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 35. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 36. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 38. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 39. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 41. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 42. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 43. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 45. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 46. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 47. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 55. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 56. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 57. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 63. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 71. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 72. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 73. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 74. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 75. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 76. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 77. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 78. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 79. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 80. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 81. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 82. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 83. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 84. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 85. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 86. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), 2018-2027 (USD MILLION)
TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), BY REGION, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), 2018-2027 (USD MILLION)
TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), BY REGION, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), 2018-2027 (USD MILLION)
TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), BY REGION, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), 2018-2027 (USD MILLION)
TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), BY REGION, 2018-2027 (USD MILLION)
TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), BY REGION, 2018-2027 (USD MILLION)
TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), 2018-2027 (USD MILLION)
TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), BY REGION, 2018-2027 (USD MILLION)
TABLE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), BY REGION, 2018-2027 (USD MILLION)
TABLE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, 2018-2027 (USD MILLION)
TABLE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2027 (USD MILLION)
TABLE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2027 (USD MILLION)
TABLE 26. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
TABLE 27. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2027 (USD MILLION)
TABLE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2027 (USD MILLION)
TABLE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, 2018-2027 (USD MILLION)
TABLE 30. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2027 (USD MILLION)
TABLE 31. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2027 (USD MILLION)
TABLE 32. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 33. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2027 (USD MILLION)
TABLE 34. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 35. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 36. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
TABLE 37. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 38. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 39. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2027 (USD MILLION)
TABLE 40. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 41. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 42. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 44. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 45. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 46. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 47. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 48. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 49. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 50. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 51. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 52. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 53. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 54. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 55. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 56. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 57. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 58. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 59. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 60. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 61. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 62. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 63. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 64. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 65. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 66. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 67. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 68. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 69. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 70. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 71. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 72. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 73. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 74. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 75. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 76. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 77. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 78. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 79. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 80. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 81. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 82. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 83. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 84. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 85. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 86. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 87. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 88. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 89. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 90. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 91. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 92. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 93. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 94. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 95. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 96. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 97. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 98. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 99. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 100. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 101. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 102. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 103. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 104. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 105. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 106. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 107. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 108. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 109. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 110. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 111. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 112. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 113. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 114. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 115. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 116. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 117. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 118. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 119. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 120. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 126. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 127. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 128. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 129. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 130. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 131. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 132. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 133. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 134. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 135. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 136. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 137. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 138. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 139. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 140. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 141. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 142. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 143. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 144. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 145. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 146. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 147. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 148. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 149. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 150. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 151. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 152. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 153. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 154. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 155. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 156. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 157. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 158. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 159. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 160. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 161. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 162. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 163. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 164. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 165. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 166. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 167. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 168. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 169. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 170. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 171. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 172. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 173. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 174. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 175. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 176. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 177. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 178. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 179. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 180. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 181. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 182. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 183. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 184. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 185. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 186. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 187. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 188. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 189. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 190. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 191. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 192. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 193. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 194. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 195. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 196. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 197. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 198. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 199. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 200. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 201. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 206. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 207. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2027 (USD MILLION)
TABLE 208. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 209. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 210. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 211. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 212. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 213. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 214. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 215. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET MERGER & ACQUISITION
TABLE 216. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 217. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 218. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET INVESTMENT & FUNDING
TABLE 219. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 220. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • Apricus Biosciences Inc.
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Cipla Ltd
  • Cristalia Produtos Quimicos Farmaceuticos Ltd.
  • Dong-A Pharmaceutical Co. Ltd.
  • Dr. Reddys Laboratories Ltd
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring Pharmaceuticals
  • Futura Medical PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc
  • Meda Pharmaceuticals, Inc.
  • Metuchen Pharmaceuticals LLC
  • Mylan N.V.
  • Novartis International AG
  • Pfizer, Inc.
  • Promedon HQ
  • S.K. Chemicals Co. Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Vivus, Inc.

Methodology

Loading
LOADING...